TNF‐alpha antagonists leads to higher improved IBDQ at weeks 6 or 8 compared with placebo (high certainty).
Infliximab leads to higher improved IBDQ at week 8 compared with placebo (high certainty).
Infliximab probably leads to higher improved SF‐36 PCS at week 8 compared with placebo (moderate certainty).
Infliximab probably leads to higher improved SF‐36 MCS at week 8 compared with placebo (moderate certainty).
Adalimumab probably leads to higher improved IBDQ at week 8 compared with placebo (moderate certainty).
Adalimumab probably leads to higher improved IBDQ at week 52 compared with placebo (moderate certainty).
Etrolizumab probably leads to lower failure to enter clinical remission at week 10 compared with placebo (moderate certainty).
Etrolizumab showed no clear difference in failure to respond at week 10 compared with placebo (moderate certainty).
Etrolizumab showed no clear difference in failure to enter endoscopic remission at week 6 compared with placebo (moderate certainty).
Etrolizumab probably leads to lower adverse events compared with placebo (moderate certainty).
Etrolizumab showed no clear difference in serious adverse events compared with placebo (low certainty).
Methotrexate showed no clear difference in remission and complete withdrawal from steroids compared with placebo (low certainty).
It is very uncertain whether methotrexate changes proportion of patients achieved clinical remission compared with 6‐mercaptopurine (very low certainty).
It is very uncertain whether methotrexate changes proportion of patients achieved clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (very low certainty).
Vedolizumab leads to lower failure to induce clinical remission compared with placebo (high certainty).
Vedolizumab probably leads to lower failure to induce clinical response compared with placebo (moderate certainty).